In today's ­first-round matchup of The Motley Fool Better Buy Tournament, Celgene (NASDAQ:CELG) squares off against Starbucks (NASDAQ:SBUX) in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts against each other as they make the case for their stocks, with the winner determined by you, the readers.

In the video below, Motley Fool analyst Max Macaluso makes the case for Celgene, a big biotech company, to move to the next round. After doubling in 2013, Celgene has faced a slow start to the year. However, the company's growing portfolio and pipeline make it a biotech to watch over the long term.

Starbucks has never been afraid of change, which is why Motley Fool Consumer Goods Editor Mark Reeth thinks it's one of the best companies on the market. Its mobile app has been a welcome addition to coffee drinkers' morning routines, with 10 million users signed up for the service. Starbucks also has been rapidly expanding overseas to great success: Revenue in the China/Asia-Pacific region was up 25% this past quarter, and that is only expected to grow. Lastly, the company is expanding its retail offerings and breaking into the tea market, which is just icing on the cake.

Watch these analysts square off in the video below and then vote for a winner. Then check out the other companies in the Motley Fool Better Buy Bracket

This year's winning stock?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Cast your vote in the poll below the video!